IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
30.46
-1.63 (-5.08%)
Mar 27, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Revenue
In the year 2025, IDEAYA Biosciences had annual revenue of $437.42M with 3,024.43% growth. IDEAYA Biosciences had revenue of $21.75M in the quarter ending December 31, 2025, with 55.37% growth.
Revenue (ttm)
$437.42M
Revenue Growth
+3,024.43%
P/S Ratio
12.23
Revenue / Employee
$1,508,345
Employees
145
Market Cap
2.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 437.42M | 423.42M | 3,024.43% |
| Dec 31, 2024 | 14.00M | -32.77M | -70.07% |
| Dec 31, 2023 | 46.77M | -55.09M | -54.08% |
| Dec 31, 2022 | 101.86M | 45.98M | 82.28% |
| Dec 31, 2021 | 55.88M | 16.81M | 43.01% |
| Dec 31, 2020 | 39.08M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Catalyst Pharmaceuticals | 588.99M |
| Travere Therapeutics | 490.73M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| Arcus Biosciences | 247.00M |
| Viridian Therapeutics | 70.85M |
| Tango Therapeutics | 62.38M |
IDYA News
- 1 day ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 6 days ago - IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial - PRNewsWire
- 10 days ago - IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - PRNewsWire
- 19 days ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - PRNewsWire
- 4 weeks ago - Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - Business Wire
- 4 weeks ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript - Seeking Alpha
- 4 weeks ago - IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer - PRNewsWire